PERSEUS Trial Adverse Events and Safety Profiles
Brea C. Lipe, MD explains common grade 3 and grade 4 adverse events observed in the PERSEUS trial.
EP: 1.Unmet Needs and Standards of Care in Multiple Myeloma
EP: 2.A Unique Drug Delivery Technology for MM
EP: 3.PERSEUS Trial Design and Overview
EP: 4.PERSEUS Trial Outcome Analysis
EP: 5.PERSEUS Trial Adverse Events and Safety Profiles
EP: 6.Integrating New Approaches to MM Treatment
EP: 7.Closing Perspectives on MM Treatment and Care
Summary
In terms of safety, the PERSEUS trial did not reveal any new or unexpected adverse events. The most common side effects were thrombocytopenia and neutropenia, consistent with the known safety profile of Dara-VRd which tends to have higher rates of cytopenia compared to VRd alone. Notably, this trial was conducted during the COVID-19 pandemic. Higher rates of infectious complications like pneumonia were seen in the Dara-VRd arm compared to VRd alone. This reinforces our understanding that quadruplets can increase susceptibility to infections, though we are learning how to better mitigate these risks. Overall, the safety profile aligned with expectations for Dara-VRD, with managing cytopenia and infections as key considerations.
Summary was AI-generated and edited for clarity.
